Advertisement

A Hodgkin lymphoma treatment, developed jointly by Cambridge-based Millennium: The Takeda Oncology Company and Washington state’s Seattle Genetics Inc., returned positive results from a pivotal trial.

The trial of 102 patients tested brentuximab vedotin (SGN-35), a treatment intended for Hodkin lymphoma and anaplastic large cell lymphoma that received orphan drug designation from the FDA and European Medicines Agency.

SOURCE

Advertisement
Advertisement